As they did with shirtless hippies in the ’60s, psychedelic drugs are having a moment—but this time around, it’s investors (with their shirts very much on) swooning over ‘shrooms.
Driving the news: Start-ups developing psychedelic drug treatments had a milestone January, bringing in US$163 million in investments, marking the second-biggest month of fundraising ever recorded for the sector, per the Financial Times.